Clinical Trials
Currently Recruiting
-
IOV-LUN-202
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04614103
-
TAC01-HER2-03
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04727151
-
Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
Sponsor: In-House
Principal Investigator: Dr. Mark Minden
NCT#: NCT02483312
-
Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
Sponsor: In-house
Principal Investigator: Drs. Lillian Siu & Anna Spreafico (Second PI)
NCT#: NCT03686202
-
Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in Phase I ImmunOncology Patients (INSPECT-IO)Eligible Tumour Type(s): Solid Cancer
Sponsor: In-house
Principal Investigator: Dr. Anna Spreafico
NCT#: NCT04107311
-
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (LANDMARC)Eligible Tumour Type(s): Epstein-Barr virus- and human papillomavirus -related cancers, Hepatocellular carcinoma
Sponsor: In-house
Principal Investigator: Dr. Kathy Han
NCT#: NCT04665388
Closed Recruiting
-
TILs-001-DC
A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT01883297
-
TILs-002-MEL
Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT01883323
https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1
-
1301-02
Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors
Sponsor: In-house (in collaboration with Takara Bio Inc)
Principal Investigator: Marcus Butler
NCT#: NCT02869217
-
TILs-003-Meso
Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT02414945
https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1